Developing Novel Solutions for the Treatment of Pain
Spinifex Pharmaceuticals is a clinical-stage Australian biotechnology company specialising in the development of products for the treatment of pain.
Spinifex focuses on pain because it is an area of high unmet medical need. Demand for pain drugs continues to increase, fuelling the growth of a market that is expected to be worth over US$35 billion by 2017(1). Chronic pain, where Spinifex is active, can have a debilitating effect on patients and is currently poorly treated. Spinifex’s lead programs are in neuropathic pain, a group of chronic painful conditions where the underlying cause is due to nerve dysfunction triggered by a variety of factors including viruses, diabetes, trauma and chemotherapy. A significant opportunity exists for new candidates that can deliver improved efficacy, side effect profiles, time to onset and simplified dosing in neuropathic pain. EMA401, Spinifex’s lead clinical candidate, is being developed to address this unmet need and has successfully completed Phase 2 clinical trials in post herpetic neuralgia, a neuropathic pain which follows herpes zoster (shingles) in some patients.
In addition, EMA401 is being advanced as a potential treatment in other chronic pain indications and Spinifex has an active drug discovery program around its AT2 Receptor Antagonist Technology.
(1) GBI Research. Pain Management Therapeutics Market to 2017 – Price Competition to Intensify Following Patent Expiries of Lyrica and Cymbalta (November 2011).
Latest News & Events
27TH MARCH 2013 Spinifex Receives $1.5m in R&D Tax Incentive for Research Activities Related to the Discovery of ... More
30TH JANUARY 2013 Pivotal EMA401 mechanism of action data has now been published in the European Journal of ... More
10TH DECEMBER 2012 Spinifex Initiates Phase 2 Proof-Of-Concept Clinical Trial in Chemotherapy Induced Neuropathy ... More